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Abstract
Background: Although hepatitis B infection is the major cause of chronic liver disease in Iran, no studies have employed economic
evaluations of the medications used to treat Iranian patients with chronic hepatitis B (CHB). Therefore, the cost-effectiveness of the
different treatment options for this disease in Iran is unknown.
Objectives: The aim of this study was to compare the cost utility and cost-effectiveness of medication strategies tailored to local
conditions in patients with HB e antigen (HBeAg)-negative CHB infection in Iran.
Methods: An economic evaluation of the cost utility of the following five oral medication strategies was conducted: adefovir (ADV),
lamivudine (LAM), ADV + LAM, entecavir (ETV), and tenofovir (TDF). A Markov microsimulation model was used to estimate the clin-
ical and economic outcomes over the course of the patient’s lifetime and based on a societal perspective. Medical and nonmedical
direct costs and indirect costs were included in the study and life-years gained (LYG) and quality-adjusted life-years (QALY) were de-
termined as measures of effectiveness. The results are presented in terms of the incremental cost-effectiveness ratio (ICER) per QALY
or LYG. The model consisted of nine stages of the disease. The transition probabilities for the movement between the different stages
were based on clinical evidence and international expert opinion. A probabilistic sensitivity analysis (PSA) was used to measure the
effects of uncertainty in the model parameters.
Results: The results revealed that the TDF treatment strategy was more effective and less costly than the other options. In addition,
TDF had the highest QALY and LYG in the HBeAg-negative CHB patients, with 13.58 and 21.26 (discounted) in all comparisons. The PSA
proved the robustness of the model results. The cost-effectiveness acceptability curves showed that TDF was the most cost-effective
treatment in 59% - 78% of the simulations of HBeAg-negative patients, with WTP thresholds less than $14010 (maximum WTP per
QALY).
Conclusions: The use of TDF in patients with HBeAg-negative CHB seemed to be a highly cost-effective strategy. Compared with the
other available medication options, TDF was the most cost-saving strategy. Thus, TDF may be the best option as a first-line medica-
tion. Patients can also be switched from other medications to TDF.
Keywords: Chronic Hepatitis B, Cost-Utility and Cost-Effectiveness Analysis, Oral Antiviral Therapy, Markov Microsimulation
Model, Probabilistic Sensitivity Analysis
1. Background
Hepatitis B remains a serious health problem world-
wide, as it is the most common and serious form of hep-
atitis and liver disease (1). People with the disease have
an increased risk of mortality and morbidity (2). In ad-
dition, treatment costs are high, especially in developing
countries (2). Currently, an estimated 350 million people
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worldwide have chronic HB (CHB) infection, which results
in about 500,000 to 1.2 million deaths per year (3, 4). In
Iran, according to the latest statistical data released by the
office for the prevention of viral hepatitis in the ministry
of health and medical education, the prevalence of hepati-
tis B in the country was estimated to be about 1.5% (5, 6).
Given that the population of Iran was about 78 million in
2014 (7), the total number of chronic HB virus (HBV) carri-
ers was estimated to be 1,170,000 people (5). The genotype
D is the predominant genotype of hepatitis in the country
(8, 9), and more than 70% of cases are HB e antigen (HBeAg)
negative (10).
Given the mortality rate among untreated CHB pa-
tients (20% - 25%) (11), long-term and severe outcomes of
CHB infection, and its complicated pattern of manage-
ment, timely diagnosis and treatment are critical to pre-
vent patients progressing to the severe stages of the dis-
ease. Although medication therapy cannot cure CHB, ex-
cept in rare cases (11), early treatment can significantly pre-
vent the progress of severe liver failure and reduce mortal-
ity (12).
Oral treatments (oral nucleos(t)ide analogues) are pre-
ferred as the first-line therapy for most genotypes of the
disease, as they have fewer side effects compared with in-
terferon (12). The goal of drug therapy for CHB patients is
to improve their quality of life and survival by preventing
progression of the disease to more severe stages, such as
liver cirrhosis and liver cancer. At present, five oral medica-
tion strategies are used to treat hepatitis in Iran: adefovir
(ADV), lamivudine (LAM), ADV + LAM, entecavir (ETV), and
tenofovir (TDF). The use of ETV is less common because of
its high cost and the fact that it is not indexed in the Iran
Drug List. However, to evaluate the cost-effectiveness of all
oral drugs in Iran, ETV was included in the studied medica-
tion strategies.
Economic evaluation studies published in recent years
showed that TDF was more cost effective than other drugs
(12-16). However, most of the published economic eval-
uation studies on CHB treatment have been carried out
in the U.S., Europe, and Southeast Asian countries. In
contrast, in the Eastern Mediterranean region, specifically
Iran, no studies have used economic evaluation models
in the assessment of medication therapy protocols for pa-
tients with hepatitis B.
Accordingly, due to the lack of sufficient scientific ev-
idence, the best strategy for the treatment of hepatitis B
patients in Iran is unclear. The provision of accurate data
on both the economic and clinical impact of HBV infection
can help policymakers to make informed decisions to pro-
vide better health and medical treatment services for these
patients. A number of factors necessitated this study. These
included the high prevalence of HBV, which accounts for
the majority of hepatitis infections in the country, its role
as the major cause of cirrhosis and liver cancer (5, 17, 18), the
need to identify optimum hepatitis B strategies tailored
to local conditions, and the absence of economic evalua-
tion studies on the disease in Iran and the Eastern Mediter-
ranean region.
2. Objectives
This study aimed to assess the cost utility and cost-
effectiveness of various medication strategies for HBeAg-
negative CHB from a societal perspective to determine the
most appropriate protocol for treating HBV infection in
Iran.
3. Methods
3.1. Overview
This study consisted of an economic evaluation of the
cost utility of five oral medication strategies: ADV, LAM,
ADV + LAM, ETV, and TDF. Unlike other studies in the field
of hepatitis, we used a Markov microsimulation model to
identify economic and clinical outcomes of HBV infection,
which requires a long-term follow up due to the chronic
and recurring nature of the infection (12). The outcome
measures used in the model included life-years gained
(LYG), quality-adjusted life-years (QALY), and the costs of
the disease and treatment strategy in each state. For ex-
tracting costs, a questionnaire was prepared, and its va-
lidity and reliability were tested. As this study adopted a
societal perspective, both medical and nonmedical costs
(direct and indirect) were evaluated. The time horizon of
the study was the patient’s lifetime, with one-year cycles,
lasting a total of 35 years. In common with other pub-
lished economic evaluation studies (12, 13) and in accor-
dance with the opinions of experts, the model was run with
one-year cycles to cope with the nature of the changes in
the various stages of the disease. As the duration of the
model in this study was more than one year, the costs and
effects of the medication therapy for patients were calcu-
lated for one year in 2014. These were discounted during
the patient’s lifetime, with an annual rate of 7.2% (19) and
3% (20), respectively. These discount rates have been ap-
plied in previous economic evaluation studies published
in Iran (21). Excel and Tree Age software, V. 2011 were used
to analyze the data.
3.2. Study Population and Treatment Regimens
The sample size of this study consisted of 155 patients
with HBeAg-negative CHB. The sample size was calculated
based on the statistical sample of the present study and the
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profiles registered in the studied centers. Therefore, the
characteristics of the patients matched those of the real
population of patients who were referred to the research
center of gastroenterology and hepatology in Baghiatol-
lah University and Baghiatollah hospital and Nemazee hos-
pital in Shiraz. The centers were selected using purposive
sampling because they are referral centers for hepatitis in
the country, and people from different parts of the country
are referred to these centers.
The mean age of the patients in the sample was 40 y,
and 67% of the study group were males.
At the end, a microsimulation analysis of a hypothet-
ical cohort population of 10000 individuals was carried
out.
3.3. Inclusion and Exclusion Criteria
The inclusion criteria were as follows: infected with
CHB, a biopsy- or fibroscan-confirmed diagnosis of CHB, re-
ceived the medications evaluated in the study for at least
one year, and had a record. The exclusion criteria were
patients with acute hepatitis B, HBeAg-positive CHB and
newly diagnosed patients, other disease states, and other
types of hepatitis.
The study was approved by the ethics committee of the
Pharmaceutical Sciences Research Center of Tehran Uni-
versity of Medical Sciences.
The medication therapy regimens included in the
model were based on the guide for the treatment of
chronic hepatitis B (22). The regimens were as follows: ADV
(10 mg daily), LAM (100 mg daily), TDF (300 mg daily), ETV
(0.5 mg daily), and a combination of ADV and LAM. All the
medications were taken orally.
3.4. Switching Medications
Based on clinical evidence worldwide (23-25) and in
Iran (26) on the development of drug resistance, side ef-
fects of drugs, or futility of drugs in some cases, medica-
tion regimens may need to be altered to enable the treat-
ment to be continued and prevent disease progression in
patients.
This study used Tree Age software to design and evalu-
ate a medication-switching model. The medications were
switched in cases of drug resistance, side effects, and no
response to the initial treatment. According to published
studies, the development of resistance was higher with
ADV and LAM than other drugs (27-30). However, as gas-
troenterology and hepatology specialists in Iran often pre-
scribe a combination of two medications (ADV + LAM and
TDF), withdrawal was designed only for these two medica-
tions, and the possibilities of resistance were considered
only for this state.
Concerning the option to switch to other medications,
according to the existing registry of gastroenterology and
hepatology Centers, 37% and 63% of patients resistant to
LAM, respectively, switched to TDF and ADV + LAM; more-
over, 48% and 52% of patients resistant to ADV, respectively,
switched to TDF and ADV + LAM.
3.5. Model Structure
Figure 1 presents a schematic diagram of the Markov
model of the studied sample and for a hypothetical cohort
population of 10000 HBeAg-negative patients aged over 18
y.
As shown in the diagram, CHB patients receiving an-
tiviral drugs can have a recurring transition to different
disease states. The specified states and their changes were
determined based on evidence from other studies and the
opinions of experts. Patients in all stages of the disease can
develop hepatocellular carcinoma (HCC) and die. The pa-
tients included in the initial distribution of the Markov mi-
crosimulation model were selected in proportion to a real
sample of patients with CHB.
3.6. Key Modeling Assumptions
Based on the available clinical evidence and the results
of a review of the medical records of the patients included
in the study, the resistance to ETV and TDF drugs was as-
sumed to be zero.
In the first five years, the drug resistance rates for both
LAM and ADV were considered to be variable (31). In subse-
quent years, they were determined based on the values in
the fifth year.
As clinical evidence suggests that combination therapy
may not result in more effective therapy (32-34) and due to
the lack of published data, it was assumed that the transi-
tion probabilities between some of the health states were
equal to the most effective component of the combination
medication shown in Table 1.
It was assumed that nucleos(t)ides had no effect on
mortality in patients with HCC and decompensated cirrho-
sis (DC).
It was assumed that the side effects associated with nu-
cleos(t)ides had no impact on cost, quality of life, and mor-
tality. Nevertheless, the cost of monitoring renal failure
was considered in the cost analysis of the model.
For some transitions, such as hepatitis B surface anti-
gen (HBsAg) to HCC, CHB to HBsAg, and CHB to UnHBV DNA
to HCC, data on the individual drugs were not available. In
these cases, it was assumed that all treated patients had an
equal chance of improvement or disease progression, irre-
spective of the type of medication used.
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Figure 1. Decision Analysis Model to Evaluate the Cost-Effectiveness of Treatment Strategies for HBeAg-Negative CHB Patients
3.7. Transitional Probabilities
Tables 1 and 2 present the transitional probabilities
for all the parameters included in the model. Due to the
absence of data from Iranian studies, especially on the
clinical efficacy of different medication protocols used for
patients with CHB, most of the transitional probabilities
between health states were extracted from international
studies and evidence on hepatitis B (12, 13, 31-49).
The mortality rate for the general population was ex-
tracted from life tables for 2012 and analyzed separately
by age and sex (50). To determine the rate of deaths due
to hepatitis B, the standardized mortality ratio reported
in published articles was used (51). Some probabilities en-
tered in the model were based on the medical records of
patients at the centers included in the study.
As the data on clinical efficacy were reported as rates in
some articles, they were converted to probabilities using
the following Formula 1 and then entered in the model:
(1)p = 1− exp(−rt)
Where p is the probability, r is the instantaneous rate,
and t is the time (52).
3.8. Health Outcomes
Health outcomes were specified in terms of LYG and
QALY. Utility scores were obtained using EQ-5D question-
naires administered via face-to-face interviews conducted
with 155 HBeAg-negative CHB patients in 2014. Related
complications, such as compensated cirrhosis (CC), DC,
and HCC, were recorded. The interviewees in the study con-
sisted of outpatients referred to the research center for gas-
troenterology and hepatology in Baghiatoallh University
in Tehran (the capital of Iran and a hepatitis referral center)
and inpatients admitted to two major hospitals in Tehran
and Shiraz. These hospitals are the main treatment centers
for liver transplantation patients.
After completing the EQ-5D questionnaire, for the first
time, we tried to consider the national values of Iran that
were obtained in a separate study by Goudarzi (53) using
time trade-off (TTO), and we changed the 5-digit codes of
the questionnaire into numerical utility (Table 3). In addi-
tion, in a separate calculation using values reported in a
U.K. study, the 5-digit codes were changed again into nu-
merical utility and used in the sensitivity analysis of the
model.
3.9. Treatment Costs
The cost analysis method used in a study performed in
2105 was applied (5). The costs of each medication strat-
egy in each state for the treatment of CHB, CC, DC, and HCC
were calculated, as shown in Table 2. Data on the direct and
indirect costs were extracted from both specialists’ and pa-
tients’ views and a review of inpatient and outpatient med-
ical records.
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Table 1. Input Parameters Used in the Economic Microsimulation Decision Model: HBeAg-Negative CHB
Variable Mean Dist Lower Values Upper Values
Prob CHB toHCCwith LAM 0.048 Beta 0.02 0.09
Prob CHB toHCCwith TDF 0.012 Beta 0.008 0.015
Prob CHB toHCCwith ADV + LAM 0.048 Beta 0.02 0.09
Prob CHB toHCCwith ETV 0.014 Beta 0.008 0.02
Prob CHB toHCCwith ADV 0.048 Beta 0.02 0.09
Prob CC to DCwith ADV 0.027 Beta 0.014 0.054
Prob CC to DCwith LAM 0.057 Beta 0.031 0.099
Prob CC to DCwith ETV 0.034 Beta 0.0063 0.0623
Prob CC to DCwith TDF 0.019 Beta 0.014 0.054
Prob CC to DCwith ADV + LAM 0.027 Beta 0.014 0.054
Prob CC to HCCwith ADV 0.039 Beta 0.02 0.071
Prob CC to HCCwith LAM 0.041 Beta 0.0092 0.0728
Prob CC to HCCwith ADV + LAM 0.039 Beta 0.02 0.071
Prob CC to HCCwith TDF 0.016 Beta 0.01 0.056
Prob CC to HCCwith ETV 0.016 Beta 0.01 0.056
ProbHCC to LT 0.008 Beta 0.00 0.031
Prob DC to LT 0.010 Beta 0.00 0.2
Prob UnHBVDNA to CHBwith TDF 0.075 Beta 0.036 0.114
Prob CHB to CCwith ADV 0.03 Beta 0.00 0.0663
Prob CHB to CCwith ADV+ LAM 0.02 Beta 0.0055 0.0345
Prob CHB to CCwith ETV 0.007 Beta 0.00 0.0157
Prob CHB to CCwith LAM 0.02 Beta 0.0055 0.0345
Prob CHB to CCwith TDF 0.006 Beta 0.00 0.0169
Prob DC to HCCwith ADV 0.065 Beta 0.022 0.074
Prob DC to HCCwith ADV + LAM 0.025 Beta 0.022 0.074
Prob DC to HCCwith ETV 0.049 Beta - -
Prob DC to HCCwith LAM 0.066 Beta 0.02 0.111
Prob DC to HCCwith TDF 0.029 Beta 0.01 0.063
Prob CHB to UnHBVDNAwith ADV 0.489 Beta 0.258 0.771
Prob CHB to UnHBVDNAwith TDF 0.938 Beta 0.796 0.993
Prob CHB to UnHBVDNAwith ADV+ LAM 0.489 Beta 0.258 0.771
Prob CHB to UnHBVDNAwith ETV 0.730 Beta 0.573 0.877
Prob CHB to UnHBVDNAwith LAM 0.381 Beta 0.337 0.424
Prob UnHBVDNA to CC 0.005 Beta 0.00 0.013
Prob UnHBVDNA to CHB 0.210 Beta 0.145 0.275
Prob UnHBVDNA to CHBwith ETV 0.075 Beta 0.036 0.114
Prob UnHBVDNA toHBsAg 0.018 Beta 0.003 0.013
Prob UnHBVDNA toHCC 0.005 Beta 0.002 0.015
ProbHBsAg to HCC 0.005 Beta 0.0004 0.041
Prob CHB toHBsAg 0.004 Beta 0.002 0.009
Prob CHB to UnHBVDNA-resistance to LAM or ADV 0.306 Beta 0.089 0.701
Prob CHB to UnHBVDNA-resistance to LAM or ADV 0.539 Beta 0.073 0.967
Abbreviations: HBeAg, hepatitis B e antigen; CHB, chronic hepatitis B; Prob, probability; CC, compensated cirrhosis; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; Sero, seroconversion; LT, liver transplantation; W,
withdrawal; LAM, lamivudine (100 mg) TDF, tenofovir (300 mg); ETV, entecavir (0.5 mg); ADV, adefovir (10 mg); HBsAg, hepatitis B surface antigen; Dist, distribution.
The costs (in US$) were based on 2014 tariffs. The ex-
change rate was 26,668 rials per dollar (54). To enable inter-
national comparisons, the costs were changed to interna-
tional dollars using a purchasing power parity (PPP) $ ex-
change rate of 8565.41 rials per 1$ (55).
3.10. Cost-Effectiveness Analysis
Based on the results of the aforementioned stages, a
model was designed using Tree Age software, and the ex-
tracted data were entered into the model. Considering the
time horizon of the study, the values for the costs, effective-
ness, and cost-effectiveness were calculated as monetary
currencies, QALY, and cost per QALY, respectively, for all the
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Table 2. Input Parameters Used in the Economic Evaluation Model: HBeAg Negative
Variable Mean Dist Lower Values Upper Values
Cost of CHBwith ADV 4256 Gamma 3405 5107
Cost of CHBwith ADV + LAM 4334 Gamma 3684 4970
Cost of CHBwith ETV 15496 Gamma 13800 18000
Cost of CHBwith LAM 4206 Gamma 3800 5000
Cost of CHBwith TDF 4922 Gamma 4100 5600
Cost of CCwith ADV 5280 Gamma 4224 6337
Cost of CCwith ADV + LAM 5358 Gamma 4600 6100
Cost of CCwith ETV 16514 Gamma 14500 18500
Cost of CCwith LAM 5231 Gamma 4500 6000
Cost of CCwith TDF 5944 Gamma 5200 6700
Cost of DCwith ADV 22476 Gamma 17980 26970
Cost of DCwith ADV + LAM 22554 Gamma 18900 26000
Cost of DCwith ETV 33709 Gamma 28000 40000
Cost of DCwith LAM 22426 Gamma 19000 26000
Cost of DCwith TDF 23139 Gamma 19000 27000
Cost of HCCwith ADV 40671 Gamma 33350 47990
Cost of HCCwith ADV + LAM 40749 Gamma 33400 48000
Cost of HCCwith ETV 51992 Gamma 45000 58000
Cost of HCCwith LAM 40621 Gamma 34000 47000
Cost of HCCwith TDF 41509 Gamma 33000 50000
Utility CHB 0.83 Beta 0.68 0.85
Utility CC 0.71 Beta 0.64 0.75
Utility DC 0.48 Beta 0.40 0.53
Utility HCC 0.51 Beta 0.27 0.59
Utility Sero 0.95 Beta 0.90 0.95
Utility UnDNA 0.83 Beta 0.77 0.85
Abbreviations: HBeAg, hepatitis B e antigen; ADV, adefovir; LAM, lamivudine; ETV, entecavir; TDF, tenofovir.
interventions and their incremental cost-effectiveness ra-
tio (ICERs) were estimated and compared using the follow-
ing Formula 2 (56):
ICERTDFvs.other antivirals
=
CostTDF − Costother antivirals
QALY/LY GTDF −QALY/LY Gother antivirals
(2)
3.11. Uncertainty Analysis
In this study, PSA was performed to evaluate the ef-
fects of uncertainty on the parameters included in the
model. The probability distributions of all the parameters
entered into the model are presented in Tables 1 and 2. A
second-order Monte Carlo simulation was performed us-
ing 5000 trials to analyze the probabilistic sensitivity. The
PSA results are presented using cost-effectiveness accept-
ability curves and a scatter plot of the incremental cost-
effectiveness. Due to the lack of an explicit WTP threshold
in Iran, based on the proposal of the world health organi-
zation for developing countries, a WTP per every QALY of
one to three times the gross domestic product per capita
was used (57). In Iran, the value in 2014 when its threefold
value was about $14010 was $4670 dollars.
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Table 3. Comparison of the Cost-Effectiveness of the Five Drug Strategies in Pa-
tients With HBeAg-Negative CHB Based on the Number of QALY Using the Markov
Microsimulation Model
Strategy Total
Cost
(USD)
LYG QALY Incr.
Cost
(USD)
Incr.
QALY
ICER
Per
QALY
Subset
-ve -ve -ve -ve -ve -ve
TDF 47,257 21.26 13.60 0 0 0 Dominated
LAM 64,096 17.69 10.93 16,839 -2.67 -6300 Dominated
ADV 69,510 18.59 11.51 22,253 -2.09 -
10622
Dominated
Lam
+ Adv
73,896 18.31 11.34 26,639 -2.27 -11743 Dominated
ETV 139,532 20.92 13.47 92,275 -0.13 -
692473
Dominated
Abbreviations: HBeAg, hepatitis B e antigen; Incr., incremental, ICER, incremen-
tal cost-effectiveness ratio; LYG, life-years gained; QALY, quality-adjusted life-
years; TDF, tenofovir; LAM, lamivudine; ADV, adefovir; ETV, entecavir.
4. Results
4.1. Base-Case Analysis
In this study, 155 HBeAg-negative CHB patients who
were referred to selected centers were enrolled in the study
and classified by age, sex, and duration of disease in the ini-
tial model. The mean age of the total sample was 40 y, 67%
of the sample were males, and 33% were females.
The results of the cost-effectiveness analysis obtained
using the Markov microsimulation model and based
on QALY and LYG showed that TDF was less expensive
and more effective than the other medication strategies.
Hence, TDF was the most cost-effective of the medication
strategies (ADV, ETV, and LAM and ADV + LAM) (Figure 2).
Table 3 presents the cost-effectiveness (QALY and LYG),
incremental costs, incremental effectiveness, and ICER, as
well as the ratings and status of domination of the five
drug therapy strategies in patients with HBeAg-negative
CHB. As shown in the table, compared with TDF, the other
strategies (LAM, ADV, ADV + LAM, and ETV) were associated
not only with lower QALY and LYG but also with higher ad-
ditional costs. During a patient’s lifetime, compared with
the alternatives, TDF had the lowest cost and highest ex-
pected QALY and LYG. ETV had the highest cost per every
unit of QALY and LYG when compared with the other strate-
gies.
4.2. Uncertainty Analysis
In this study, PSA was used to measure the effects of
uncertainty in the parameters on the results of the model.
Using 5000 trials, a second-order Monte Carlo simulation
and PSA were conducted. The uncertainty of the results
based on the range of WTP thresholds, cost-effectiveness
acceptability curves, and a scatter plot of the incremental
cost-effectiveness are presented in Figures 3 and 4.
An acceptability curve is one of the best curves for
planning and policymaking. It can help policymakers and
health system planners determine the cost-effectiveness of
every intervention per payment. The results of the accept-
ability curves showed that TDF was the most cost-effective
treatment strategy in 59% - 78% of simulations for thresh-
olds below $14010 for patients with HBeAg-negative disease
(Figure 3).
By showing what percentage of points is located in the
accepted area (below the threshold), scatter plots present
more detailed information for comparisons between sin-
gle drugs. The scatter plot results are presented only for
TDF compared with the alternatives. As compared with
LAM, ADV, ETV, and ADV + LAM, the results demonstrated
that TDF was in an acceptable area below the threshold
in 85%, 84%, 62%, and 83% of cases in patients with HBeAg-
negative disease. Hence, it was the best of the other alterna-
tives and the most cost-effective strategy (Figure 4). There-
fore, the results of the sensitivity analysis did not change
the status of TDF as the most effective treatment. This find-
ing is an indication of the robustness of the results of the
study.
5. Discussion
This is the first comprehensive economic evaluation
study of hepatitis B patients in Iran and the Eastern
Mediterranean region. The study aimed to evaluate oral
nucleos(t)ide analogue strategies for HBeAg-negative CHB
and its related complications from a pharmacoeconomic
societal perspective.
In the present study, the ICERs based on QALY and LYG
in patients with HBeAg-negative CHB showed that of the
five therapeutic strategies (ADV, LAM, ADV + LAM, ETV, and
TDF) used in Iran, TDF was more effective and less expen-
sive. This finding is in line with the results of He et al.’s
study (12) and Tantai et al.’s study (58). Despite some mi-
nor differences, the results of this study are also consis-
tent with those of previously published economic evalua-
tion studies of HBV, such as the CUA study by Dakin et al.
in the U.K. (13) and Buti et al. ‘s study (56) in Spain. The
results of the present study demonstrated that TDF in pa-
tients with HBeAg-negative CHB had the lowest expected
cost and highest expected QALY and LYG in a lifetime span.
The results of this study are consistent with those of Tantai
et al. (58).
The results of the PSA revealed that TDF was less ex-
pensive and more effective than the other drug therapy
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strategies and that it achieved the best results. It also con-
firmed that TDF was superior to all the other drug treat-
ment strategies. As the results of the PSA did not alter the
status of TDF as the most effective treatment, the results of
the present study seem to be robust. The findings of the
current study are in line with those of studies by He et al.
in Canada, Wiens in Brazil, and Tantai et al. in Thailand (12,
16, 58).
The cost-effectiveness acceptability curve, which was
the output curve of PSA, also showed that TDF was the most
cost-effective therapy in 59% - 78% of simulations in HBeAg-
negative cases for thresholds below $14010. The results of
this study are consistent with those an earlier study by He
al. (12), who reported that TDF was the most effective strat-
egy in 65% - 78% of cases.
Furthermore, as shown by the results of the incremen-
tal cost-effectiveness scatter plot, which was another out-
put of the PSA, in most cases, compared with the other al-
ternatives, TDF was in an acceptable area below the thresh-
old. In patients with HBeAg-negative CHB, compared with
the alternatives (LAM, ADV, ETV, and ADV + LAM), TDF was in
acceptable area below the threshold in 85%, 84%, 62%, and
83% of cases and was superior to the other strategies. The
results of the present study are in line with those of He et
al. (12).
In addition, the results obtained from the estimation
of QALY and cost savings associated with the use of TDF in
HBeAg-negative patients compared with the alternatives
showed that it reduced the progress of the disease and se-
rious complications in the future. In addition, it led to cost
savings and a very significant increase in the number of
QALYs. The results of this study are consistent with those
of studies conducted by Jing et al. and Tantai et al. (12, 58).
TDF seems to be the optimal drug regimen to stop or slow
the progression of liver disease. Therefore, TDF, which was
identified as the most cost-saving strategy in this study and
8 Hepat Mon. 2016; 16(9):e37435.
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Figure 4. Incremental Cost-Effectiveness of TDF Compared With the Other Antivirals (ADV, LAM, LAM + ADV, and ETV)
The scatter plots show the difference in cost and QALY results of 5000 simulations.
some previously published studies (12, 16, 58), should be
the first choice in cases of LAM or ADV drug resistance.
Most of the drugs in the present study are manufac-
tured in Iran and therefore do not require high expendi-
tures by either patients or the health system. However,
given the better response of TDF compared with the other
drugs, it can prevent and reduce high costs associated with
complications (i.e., cirrhosis and cancer) that emerge in se-
vere stages of the disease. A regular review of the literature
after the introduction of new drugs can ensure that the
dominant drugs are excluded and replaced by the domi-
nant drugs. This will benefit all those involved in the health
system (i.e., the government, insurance industry, and pa-
tients).
The strengths of this study are as follows: The model in-
cluded both direct medical and various indirect nonmedi-
cal costs, and it employed the Monte Carlo Markov method
for microsimulation modeling. In addition, the data on
the costs and effectiveness were collected locally and based
on observations, patients’ self-reports, and experts’ opin-
ions. Furthermore, the values of the country were used for
the first time to convert the 5-digit code numbers of the
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questionnaire to numerical utility. An additional strength
of the model used in the study was the ability to switch to
another drug therapy for those patients who gave up drug
therapy. This ability distinguishes the present model from
models used in previous studies. Finally, for the first time,
a microsimulation approach was used to assess the cost-
effectiveness of antiviral drugs in patients with chronic
HBV infection.
One of the limitations of this study was the absence of
data in some cases, especially data on the transitional prob-
abilities of the disease. Hence, a constant rate was used in
this study. Although the results showed that TDF was the
superior and most cost-effective option for HBeAg-negative
patients, to generalize the results to other settings, various
factors could influence the findings. These include the epi-
demiology of the disease, demographics of the study pop-
ulation, resource availability, costs, valuing outcomes by
individuals, thresholds, and the use of indicators of effec-
tiveness. However, as this study included a range of impor-
tant features of the patients, including age, sex, and dura-
tion of the disease, and the data were extracted from sev-
eral main referral centers in the country, many of the re-
sults can likely be generalized.
In conclusion, according to the results of this study,
among nucleos(t)ide analogues evaluated, TDF was the op-
timal and most cost-effective strategy for patients with
CHB. Hence, it can be used as first-line therapy and for pa-
tients switching from other drugs. Furthermore, as TDF
can reduce treatment times and manage drug resistance,
TDF can be recommended as first-line therapy for patients
with CHB.
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